Author:
Kanavos Panos,Reinhardt Uwe
Publisher
Health Affairs (Project Hope)
Reference11 articles.
1. P.M. Danzon , “Pharmaceutical Benefit Management: An Alternative Approach,”Health Affairs(Mar/Apr 2000 ): 24 –25, quote at 25.
2. B. Jönsson , “Reference Pricing: Central Economic and Policy Issues,” inReference Pricing and Pharmaceutical Policy,ed. G. Lopez-Casasnovas and B. Jönsson (Barcelona: Springer Verlag Ibéria, 2001 ), 82 –83.
3. D.J. Birkett , A.S. Mitchell, and P. McManus, “A Cost-Effectiveness Approach to Drug Subsidy and Pricing in Australia,”Health Affairs(May/June 2001 ): 104 –114
4. ; and R. Braae , W. McNee, and D. Moore, “Managing Pharmaceutical Expenditure while Increasing Access: The Pharmaceutical Management Agency (PHARMAC) Experience,”Pharmacoeconomics(December 1999 ): 649 –660.
5. H.A. Huskamp et al. “The Medicare Prescription Drug Benefit: How Will the Game Be Played?”Health Affairs(Mar/Apr 2000 ): 8 –23.
Cited by
84 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Arzneiverordnungen 2022 im Überblick;Arzneiverordnungs-Report 2023;2023
2. Arzneiverordnungen 2021 im Überblick;Arzneiverordnungs-Report 2022;2022
3. Leistungsmanagement;Management im Gesundheitswesen;2022
4. Arzneiverordnungen 2020 im Überblick;Arzneiverordnungs-Report 2021;2021
5. Should the United States government regulate prescription prices? A critical review;Research in Social and Administrative Pharmacy;2020-05